-transparent.png){kind=logo}
Despite better control of diabetic patients with morbidity and mortality from heart disease is significantly higher than in non-diabetics. While this may be a result of premature atherosclerosis or primary diabetic cardiopathy, the possibility of oral hypoglycemic agents have adverse cardiac effects must be considered. Using nuclear angiography the effect of the acute administration of 1 g tolbutamide on left ventricular ejection fraction (EF) in a group of 10 Type-1 diabetics was investigated. There was no difference in the response of the EF when compared to the response in 10 diabetic controls given i.v. saline. While i.v. tolbutamide may have adverse cardiac effects when administered to animals or in vitro this does not necessarily apply to human diabetics.
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
January 1979,
The Tohoku journal of experimental medicine,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
January 1983,
Acta medica Scandinavica,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
June 1986,
Diabete & metabolisme,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
October 1993,
Annales de cardiologie et d'angeiologie,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
December 1988,
The Journal of the Association of Physicians of India,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
January 1986,
Cardiology,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
January 1988,
Acta physiologica Hungarica,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
October 1987,
Clinical cardiology,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
February 1969,
Diabetes,
A D Harrower, and
R D Adam, and
G McFarlane, and
R Railton, and
K C Young
April 1970,
Acta medica Scandinavica,
